Category → Cool Stuff
Watch Twitter on Saturday for #Chemophobia
This week, the Research Triangle area is hosting ScienceOnline2013, an international science communications unconference that draws Pulitzer Prize-winning science writers, big media, graduate students, new media, science teachers, old media – pretty much anyone who’s involved in communicating science to diverse audiences via digital media.
The gathering began as the North Carolina Science Blogging Conference in 2007 (and probably before that) and has grown to be a highly-competitive ticket for 450 attendees. So popular are the conversations there that “watch parties” are being held in cities worldwide – London, Paris, Adelaide, Denver, Dublin, Belgrade, and others.
But the conversation can also be easily accessed via Twitter by following the hashtag #scio13.
I’d love to draw the C&EN and CENtral Science crowd to a superb session that will be held Saturday, 2 February, with our own Dr. Carmen Drahl and chemistry professor/former ACS intern Dr. Rubidium on chemophobia: the public aversion to anything that carries the label of “chemical.”
Here’s the description from the unconference wiki for tomorrow’s 10:30 am EST session:
Description: In today’s advertising and pop culture, words like “chemical”, “synthetic” and “artificial” are synonyms for harmful, toxic and carcinogenic, while words like “natural” and “organic” imply a product is wholesome and good for the environment. This widespread misconception colors public perceptions of chemistry and its role in the modern world. Chemophobia may not be as direct a threat to our future as, say, climate change denialism or the Israeli-Palestinian crisis, but it clouds public understanding of real and very important issues we face (e.g., how to boost agricultural productivity) and plays into the hands of quacks and cranks. How can bloggers and the media effectively combat chemophobia? How much chemistry does the public need to know to be well-informed and make good decisions, and what’s the most effective avenue for disseminating that kind of information? Proposed session hashtag: #chemophobia
Over the past year, several folks in the blogosphere and chemistry education realm have been providing folks like Carmen, DrR, and author Deborah Blum with examples of chemicals being portrayed as “bad.”
Yet, each of us are a glorious bag of chemicals (thankfully).
Where does the negative perception arise and how can we in chemistry-related fields better communicate with the public?
Carmen and DrRubidium have asked us to follow the #chemophobia hashtag on Saturday 10:30-11:30 am EST.
Here’s a world clock so you can plan when to follow the discussion on Twitter.
Lefkowitz IndyWeek Outtakes
The 9 January 2013 edition of the Research Triangle area’s alternative weekly newspaper, INDY Week. Photo: D.L. Anderson/INDY Week. Click on the photo to go the online article.
I was fortunate to be able to tell the story of Duke University biochemist and cardiologist Dr. Robert J. Lefkowitz in the 9 January 2013 issue of the Research Triangle’s award-winning alt-weekly, INDY Week.
Even with editor Lisa Sorg graciously offering 3,000+ words for the story on one of the 2012 Nobel laureates in chemistry, some terrific bits of my interviews with Bob and major players in his story didn’t make it into the final version.
Over the next few days, I’ll post some of these gems. This page will index the running list of those posts.
The Nobel’s Great, But Take a Look at This! – Lefkowitz reveals where Duke men’s basketball sits in his list of priorities
Helping Schools Hit By Sandy
Terra Sig’s Post-Sandy Science Drive
During the month of October, I had usually participated in a science blog drive to raise funds for public school teachers through a superb, New York-based charitable organization called DonorsChoose.com.
For those not familiar, the non-profit was the brainstorm of Charles Best was a Bronx high school history teacher who, like many others, spent a considerable amount of his personal funds on resources and supplies for his students. Best came up with an idea for an online giving site where teachers could match specific projects to parents and other external donors — “where anyone with $5 can become a philanthropist.”
How it works.
The entire story is here but DonorsChoose has been a remarkable success.
Many science bloggers became involved with DonorsChoose as far back as 2006 due to the efforts of physical chemist, philosopher, and science ethicist Dr. Janet Stemwedel. While we were at ScienceBlogs.com, Janet corralled the entire network and then other blogging networks into a month-long challenge where we asked our readers to spare a few doubloons for projects we thought would appeal to our audience.
Elion-Hitchings Building Tour: A Storify
Burroughs-Wellcome Elion-Hitchings Building Open for Public Tours October 20th Only
I’m not an architect but I absolutely love quirky and creative buildings. During the eight years I lived in the foothills outside of Denver, I passed the clamshell-shaped home featured in Woody Allen’s 1973 movie, “Sleeper” – yes, the home with the Orgasmatron (a prop made from a cylindrical door like those used for research darkrooms).
For you youngsters who may not know what I’m talking about, here’s a two-minute movie clip that’s probably safe for work.
Well, from that era is another futuristic building designed by Paul Rudolph and completed in 1971 — then known as the Burroughs-Wellcome Headquarters Building in Research Triangle Park.
Click on the photo for information about the tour this Saturday, 20th October. Photograph reprinted courtesy of the Research Triangle Foundation of North Carolina.
Gurdon and Yamanaka share Nobel Prize in Physiology or Medicine 2012
British scientist John B. Gurdon and Shinya Yamanaka (MD, PhD!), a Japanese scientist now at the Gladstone Institutes in San Francisco, were awarded the Nobel Prize in Physiology or Medicine this morning, ”for the discovery that mature cells can be reprogrammed to become pluripotent.”
John B. Gurdon. Credit: nobelprize.org, Creative Commons Attri 2.0 license.
Briefly, Gurdon and colleagues showed that the genetic information from a mature, differentiated cell still had the ability to program an undifferentiated embryonic cell to develop into an adult organism. That is, an embryonic cell contains the chemical signals to use adult DNA to drive development of a new organism.
The work was done with the frog, Xenopus laevis, and the technique came to be known as “nuclear transfer.” In colloquial terms, this is “cloning.” Current press reports are citing Gurdon’s work as occurring in 1962 but studies appear to have been published in Nature as early as 1958.
Christen Brownlee composed a superb summary of nuclear transfer for the Classics section of the Proceedings of the National Academy of Sciences. Gurdon’s work stemmed from 1952 experiments of Robert Briggs and Thomas J. King with another frog, Rana pipens. Briggs died in 1983 and King in 2000 and could not be recognized with the Nobel. This fact relieved the Nobel committee, in my opinion, from having to decide which scientist would have been awarded the potential third slot for the prize. (Addendum 7:18 am EDT): I suspect that some argument will arise in support of UW-Madison’s James A. Thomson for the third slot as the Science paper from his group came out concomitantly with Yamanaka’s Cell paper. 8:21 am: The Guardian’s Alok Jha just reminded me that I overlooked Takahashi and Yamanaka’s earlier Cell paper from 2006. However, C&EN’s Carmen Drahl is now reporting this 2001 TIME magazine cover with Thomson.)
Antibody-drug conjugates: not exactly “smart bombs” for cancer
Antibody-drug conjugates are the cover story in the 18 June 2012 issue of C&EN. Illustration credit: ImmunoGen.
I only have a quick post today because I really want you to spend your reading energy on a superb C&EN cover story by my colleague here, Lisa M. Jarvis.
The media frenzy that normally follows the American Society of Clinical Oncology (ASCO) meeting each June focused this year on cancer cell-directed antibodies conjugated to highly-cytotoxic compounds. The most ballyhooed of these is T-DM1, the anti-HER2 trastuzumab antibody (Herceptin) covalently linked to the microtubule-inhibiting maytansine analog, DM1 (meeting abstract, Genentech press release). When the conjugate is internalized by breast cancer cells overexpressing the HER2 protein, the highly-toxic DM1 drug is released intracellularly.
Talking fungi at Skeptically Speaking
A brainy, free, and fun online and radio chat-type call-in show on all things science. Hosted by Desiree Schell and edited by K.O. Myers. Awesomesauce. From Canada, of course.
Well, if you’re looking for something to do during Super Bowl halftime than watch Madonna, you’re welcome to join me online for the wildly-successful science radio show, Skeptically Speaking.
With Edmonton-based host Desiree Schell (@teh_skeptic) and her US-based producer K.O. Myers (@KO_Myers), we’ll be discussing the secret lives of fungi, particularly as related to the synthesis of secondary metabolites that we use as therapeutic agents.
If you’re able to join us live, we’ll be at this UStream.tv page at 8 pm Eastern, 6 pm Mountain. On the chat bar at the right of the page, you can follow the online discussion and submit questions of your own.
I hope that you can dial us in. If not, the complete podcast will be downloadable on the evening of February 10.